Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
BUSINESS
SanBio, Minaris Aim to Expand Global Reach of Akuugo
SanBio and CDMO partner Minaris Advanced Therapies are aiming to bring the cell therapy Akuugo (vandefitemcel) to global markets and expand its indications as the product edges closer to shipment approval in Japan. At a media tour of Minaris’ CDMO…
To read the full story
Related Article
- SanBio’s Akuugo Nears Shipment with MHLW Panel Backing; Sakigake Tag OK’ed for Bayer Gene Therapies
October 17, 2025
- SanBio’s Akuugo Set for Re-Review on Oct. 16, Shipment Decision Nears
October 3, 2025
- SanBio Eyes Akuugo Label Expansion Talks with PMDA in FY2026
September 19, 2025
- SanBio Pushes Back Shipment Approval Timeline for Cell Therapy Akuugo
June 26, 2025
- SanBio Inches Closer to Cell Therapy Shipment with Partial Change Filing
June 13, 2025
- SanBio’s Cell Therapy Akuugo Scores Conditional Approval
August 1, 2024
- SanBio Says Its Lead Cell Therapy Could Be Shipped from 2025 If All Goes Well
June 21, 2024
- SanBio’s Lead Cell Therapy in Line for Conditional Nod but Can’t Be Shipped Until Comparability Is Confirmed
June 20, 2024
- SanBio’s Lead Cell Therapy Up for Review Again on June 19
June 14, 2024
- SanBio to Submit Additional Data to Obtain Approval for Lead Cell Therapy
March 27, 2024
- Japan Shelves Decision on SanBio’s Lead Cell Therapy on Quality Concerns
March 26, 2024
BUSINESS
- Eylea Bio-AG to Carry DME Indication Missing from Fuji’s Biosimilar Label
December 5, 2025
- Forxiga Generics Launch in Japan at 33.6% of Originator Price: Sawai, T’s Pharma
December 5, 2025
- Vimpat Copies Hit Shelves at 35% of Originator Price as 10 Firms Flock to Market
December 5, 2025
- Keytruda Extends Japan Sales Lead to 26 Straight Months in November: Encise
December 5, 2025
- Meiji Pharma Takes Stake in Lyric Bio to Back Next-Gen IVIg Manufacturing
December 5, 2025
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…